Johnson & Johnson MedTech recently launched their Cereglide 92 catheter system for the treatment of acute ischemic stroke.

Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said.

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ...

TECLens Inc., a Stamford-based clinical-stage ophthalmic medical device company, said Tuesday it raised $9.3 million in a ...

Johnson & Johnson (NYSE:JNJ), the New Jersey-based healthcare company, is planning to sell its stroke care business, ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Johnson & Johnson aims to streamline operations by selling its stroke care business, Cerenovus, valued at $1B+.

Have you ever thought about how medical devices designed to improve lives can sometimes cause harm instead? This became evident in August 2024, when a landmark settlement in England saw 140 women ...

Will there be a severe downturn as a result? No one can say for sure, but investing in companies that can handle market ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...